Payment overview · 2025
General Payments
$520.01
21 reported records · 8 companies
Healthcare provider profile · identity verified
Satiskumar P Patel, M.D. MBCHB
Allopathic & Osteopathic Physicians|Internal Medicine · DAYTON, TX · NPI 1659303824
Verified facts
What the public records show
CMS Open Payments records show Satiskumar P Patel, M.D. MBCHB received $520.01 in general payments during 2025 across 21 reported records.
Inspire Medical Systems, Inc. accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $151.79 | 29.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $142.53 | 27.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.20 | 11.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.86 | 9.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.29 | 6.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.24 | 5.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.23 | 5.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.87 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.01 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $151.79 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $142.53 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.20 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.86 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.71 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 493 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 155 |
| Lisinopril | Lisinopril | 408 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 119 |
| Glipizide Er | Glipizide | 277 | 99 |
| Gabapentin | Gabapentin | 276 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 92 |
| Doxazosin Mesylate | Doxazosin Mesylate | 234 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 213 | 67 |
| Losartan Potassium | Losartan Potassium | 186 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 63 |
| Benazepril Hcl | Benazepril Hcl | 158 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 53 |
| Furosemide | Furosemide | 151 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 151 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 149 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 53 |
| Meloxicam | Meloxicam | 142 | 59 |
| Lovastatin | Lovastatin | 141 | 42 |
| Carvedilol | Carvedilol | 130 | 48 |
| Omeprazole | Omeprazole | 129 | 45 |
| Montelukast Sodium | Montelukast Sodium | 120 | 41 |
| Potassium Chloride | Potassium Chloride | 118 | 45 |
| Trazodone Hcl | Trazodone Hcl | 117 | 45 |
| Eliquis | Apixaban | 116 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 28 |
| Metformin Hcl | Metformin Hcl | 111 | 45 |
| Nifedipine Er | Nifedipine | 109 | 35 |
| Allopurinol | Allopurinol | 106 | 34 |
| Simvastatin | Simvastatin | 104 | 34 |
| Celecoxib | Celecoxib | 102 | 37 |
| Ozempic | Semaglutide | 99 | 30 |
| Metformin Hcl Er | Metformin Hcl | 96 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 34 |
| Sertraline Hcl | Sertraline Hcl | 93 | 35 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 87 | 16 |
| Alprazolam | Alprazolam | 84 | 22 |
| Jardiance | Empagliflozin | 84 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 25 |
| Ezetimibe | Ezetimibe | 78 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Methylprednisolone | Methylprednisolone | 74 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 23 |
| Aripiprazole | Aripiprazole | 65 | 23 |
| Bupropion Xl | Bupropion Hcl | 65 | 19 |
| Glipizide | Glipizide | 65 | 24 |
| Valsartan | Valsartan | 65 | 28 |
| Naproxen | Naproxen | 62 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 15 |
| Xarelto | Rivaroxaban | 56 | 12 |
| Lorazepam | Lorazepam | 55 | 18 |
| Cefdinir | Cefdinir | 47 | 45 |
| Donepezil Hcl | Donepezil Hcl | 46 | 16 |
| Glimepiride | Glimepiride | 46 | 17 |
| Clonazepam | Clonazepam | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 16 |
| Atenolol | Atenolol | 44 | 16 |
| Buspirone Hcl | Buspirone Hcl | 44 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 37 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 42 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 18 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 31 |
| Clonidine Hcl | Clonidine Hcl | 38 | 12 |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Famotidine | Famotidine | 37 | 13 |
| Lactulose | Lactulose | 37 | 19 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 12 |
| Ibuprofen | Ibuprofen | 31 | 16 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 11 |
| Ketoconazole | Ketoconazole | 29 | 17 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 13 |
| Azithromycin | Azithromycin | 28 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 13 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | 15 |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 13 |
| Methocarbamol | Methocarbamol | 24 | 15 |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Prednisone | Prednisone | 23 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | 11 |
| Baclofen | Baclofen | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Dutasteride | Dutasteride | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.01 · 21 records | Inspire Medical Systems, Inc. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, GEMTESA, INSPIRE, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error